 |
|
Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer
A. Heather Eliassen, ScD;
Graham A. Colditz, MD, DrPH;
Bernard Rosner, PhD;
Walter C. Willett, MD, DrPH;
Susan E. Hankinson, ScD
Arch Intern Med. 2005;165:2264-2271.
Background Experimental evidence suggests that statins protect against breast carcinogenesis by interrupting cell cycle progression and promoting apoptosis. Evidence in humans is limited and inconsistent. The relation between serum cholesterol levels and breast cancer risk is itself unclear; because cholesterol is the precursor to sex steroid hormones, higher levels could plausibly increase risk.
Methods The associations of statins, general lipid-lowering drugs, and reported cholesterol levels with breast cancer risk were assessed in the Nurses’ Health Study, with 6 to 12 years of follow-up. A total of 79 994 women aged 42 to 69 years and free of cancer were followed prospectively for up to 12 years. Current statin use, including duration, was assessed retrospectively in 2000 in 75 828 women. Self-reported serum cholesterol level was assessed prospectively between 1990 and 2000 in 71 921 women.
Results Overall, we documented 3177 incident cases of invasive breast cancer. Compared with nonusers, current lipid-lowering drug users experienced similar breast cancer risk (multivariate relative risk [RR], 0.99; 95% confidence interval [CI], 0.86-1.13). Current use of statins also was not significantly associated with breast cancer risk (RR, 0.91; 95% CI, 0.76-1.08). Associations by duration of current use were similarly null. Self-reported serum cholesterol levels were not associated with breast cancer risk in postmenopausal women with levels of 240 mg/dL or higher ( 6.22 mmol/L) compared with less than 180 mg/dL (<4.66 mmol/L) (RR, 1.04; 95% CI, 0.91-1.17).
Conclusion Overall, these data suggest that serum cholesterol levels and the use of lipid-lowering drugs in general and of statins in particular are not substantially associated with breast cancer risk.
Author Affiliations: Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (Drs Eliassen, Colditz, Rosner, Willett, and Hankinson); and Departments of Epidemiology (Drs Eliassen, Colditz, and Hankinson), Biostatistics (Dr Rosner), and Nutrition (Dr Willett), Harvard School of Public Health; Boston, Mass.
RELATED LETTERS
Clinical Trials Are Required to Prove the Chemopreventive Worth of Statins
Anjali S. Kumar, Christopher C. Benz, and Laura J. Esserman
Arch Intern Med. 2006;166(10):1143.
EXTRACT
| FULL TEXT
Breast Cancer Prevention: Time for Randomized Controlled Trials With Statins
Julian Sprague and Marie Wood
Arch Intern Med. 2006;166(10):1143-1144.
EXTRACT
| FULL TEXT
Breast Cancer Prevention: Time for Randomized Controlled Trials With Statins—Reply
A. Heather Eliassen and Susan E. Hankinson
Arch Intern Med. 2006;166(10):1144.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Samson
VASC ENDOVASCULAR SURG 2008;42:352-366.
ABSTRACT
Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
Kumar et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1028-1033.
ABSTRACT
| FULL TEXT
Statins, Breast Cancer, and an Invisible Switch?
Byers
Cancer Epidemiol. Biomarkers Prev. 2008;17:1026-1027.
FULL TEXT
The Association Between Statins and Cancer Incidence in a Veterans Population
Farwell et al.
JNCI J Natl Cancer Inst 2008;100:134-139.
ABSTRACT
| FULL TEXT
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence
Xue and Michels
Am. J. Clin. Nutr. 2007;86:823S-835S.
ABSTRACT
| FULL TEXT
C-Reactive Protein and Risk of Breast Cancer
Zhang et al.
JNCI J Natl Cancer Inst 2007;99:890-894.
ABSTRACT
| FULL TEXT
Statin Use and Breast Cancer Risk in a Large Population-Based Setting
Boudreau et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:416-421.
ABSTRACT
| FULL TEXT
Pravastatin and cancer: an unproven association
Brophy
CMAJ 2007;176:646-647.
FULL TEXT
Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Setoguchi et al.
Circulation 2007;115:27-33.
ABSTRACT
| FULL TEXT
Statin Drugs and Risk of Advanced Prostate Cancer
Platz et al.
JNCI J Natl Cancer Inst 2006;98:1819-1825.
ABSTRACT
| FULL TEXT
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Sivaprasad et al.
Molecular Cancer Therapeutics 2006;5:2310-2316.
ABSTRACT
| FULL TEXT
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Kelloff et al.
Clin. Cancer Res. 2006;12:3661-3697.
ABSTRACT
| FULL TEXT
Clinical trials are required to prove the chemopreventive worth of statins.
Kumar et al.
Arch Intern Med 2006;166:1143-1143.
FULL TEXT
Breast Cancer Prevention: Time for Randomized Controlled Trials With Statins--Reply
Eliassen and Hankinson
Arch Intern Med 2006;166:1144-1144.
FULL TEXT
Breast cancer prevention: time for randomized controlled trials with statins.
Sprague and Wood
Arch Intern Med 2006;166:1143-1144.
FULL TEXT
Statin use and breast cancer: prospective results from the Women's Health Initiative.
Cauley et al.
JNCI J Natl Cancer Inst 2006;98:700-707.
ABSTRACT
| FULL TEXT
In Reply
Bonovas et al.
JCO 2006;24:2129-2129.
FULL TEXT
Statin Use Not Associated with Breast Cancer Risk
Journal Watch Cardiology 2005;2005:5-5.
FULL TEXT
|
